• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
Gastrointestinal RSS Feed RSS

Gold Euro symbol on blue background

Amid shifting MASH landscape, Inventiva adds €348M financing

Oct. 15, 2024
By Nuala Moran
Inventiva SA is back on course to complete phase III development of its metabolic dysfunction-associated steatohepatitis (MASH) drug, lanifibranor, after putting in place new financing of up to €348 million (US$379.4 million), including an immediate cash injection of €94.1 million.
Read More

Topas’ platform validated with top-line celiac disease data

Oct. 15, 2024
By Karen Carey
Securing clinical proof of concept for its nanoparticle platform, Topas Therapeutics GmbH reported promising top-line phase IIa results of TPM-502 for celiac disease. Results show a clear statistically significant dose response for antigen-specific markers of tolerance. The effects persisted throughout the follow-up period, and the candidate was safe at all doses tested, according to the Hamburg, Germany-based company.
Read More
Art concept for inflammation in the intestines
Gastrointestinal

SPY-001 antibody shows extended half-life for treating IBD

Oct. 15, 2024
Recent advances in the management of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, have shown that inhibiting the interaction between the α4β7 integrin and the endothelial ligand mucosal addressin cell adhesion molecule 1 (MADCAM1) has proven useful, safe and effective.
Read More
3D illustration of human digestive system
Gastrointestinal

Redx Pharma’s RXC-008 suppresses fibrosis in preclinical IBD

Oct. 15, 2024
At the United European Gastroenterology Week in Vienna, Redx Pharma plc presented data regarding their ROCK inhibitor RXC-008 for treating fibrostenotic Crohn’s disease. RXC-008 is restricted to the gastrointestinal tract, thus avoiding systemic exposure; ROCK1/2 kinases are involved in fibrosis and their blockade has been efficacious in several rodent models of fibrotic disease.
Read More
Liver and DNA
Gastrointestinal

Proqr Therapeutics RNA editing technology counteracts cholestatic disease

Oct. 14, 2024
Researchers from Proqr Therapeutics NV recently presented preclinical data on AX-0810, a single-stranded RNA editing oligonucleotide (EON) targeting RNA coding for NTCP cotransporter
Read More

Upstream, Camp4 price upsized IPOs

Oct. 11, 2024
Coming off September, which saw five biopharma IPOs raise more than $1 billion, two firms priced upsized offerings that could total more than $330 million.
Read More
Two arrows in opposite directions

Gilead ends $785M Yuhan deal for small-molecule MASH drugs

Oct. 11, 2024
By Marian (YoonJee) Chu
Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis (MASH) therapies.
Read More
Endostart Endorail system

Endostart gains CE mark for Endorail use in the small bowel

Oct. 11, 2024
By Shani Alexander
Endostart s.r.l obtained CE marking for the expanded use of its magnetic balloon system for use in endoscopic procedures, Endorail, to enteroscopy. The company believes that Endorail, which helps resolve intestinal looping, will make the procedure more accessible and improve patient care.
Read More
Clostridium difficile bacteria
Infection

A novel mRNA-LNP vaccine facilitates Clostridioides difficile control

Oct. 11, 2024
By Coia Dulsat
Clostridioides difficile is traditionally isolated from healthcare facilities' inpatients, but it is increasingly being identified in people who have not recently been hospitalized and is more and more found in community settings. Investigators from Perelman School of Medicine at University of Pennsylvania developed an mRNA-LNP vaccine with promising results in preventing and controlling C. difficile infection.
Read More
Clostridium difficile bacteria

A novel mRNA-LNP vaccine facilitates Clostridioides difficile control

Oct. 11, 2024
By Coia Dulsat
Clostridioides difficile has been traditionally isolated from health care facilities' inpatients, but it is increasingly being identified in people who have not recently been hospitalized and is more and more found in community settings. Investigators from Perelman School of Medicine at University of Pennsylvania have developed an mRNA-LNP vaccine with promising results in preventing and controlling C. difficile infection.
Read More
Previous 1 2 … 14 15 16 17 18 19 20 21 22 … 705 706 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 27, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 27, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • Andembry

    New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema

    BioWorld
    Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe